Voriconazole in Prevention and Treatment of Febrile Neutropenia
AbstractInvasive fungal infections are one of important complication in patients receiving chemotherapy or hematopoietic stem cell transplantation. Voriconazole is a triazole antifungal agent widely used for prophylaxis and treatment of fungal infections. It is also administered for empiric treatment of fungal infections in patients with febrile neutropenia.Although amphotericin B preparations and fluconazole generally are used for empiric antifungal therapy and antifungal prophylaxis, but it should be noted that there are insufficient data to draw any firm conclusion about use of other new alternatives as drug of choice.This paper will review the researches that conducted on voriconazole as an empiric antifungal therapy or antifungal prophylaxis in patients with neutropenia following chemotherapy or HSCT.
Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis, 2003; 36:630–637.
Wang T, Zhu H, Sun J, Cheng X, Xie J, Dong H, Chen L, Wang X, Xing J, Dong Y. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimized dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents, 2014; 44:436–442.
Florent A, Gandia P, Seraissol P, Chatelut E, Houin G. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment. Ther Drug Monit, 2014; 36:752–758.
Sandherr M, Maschmeyer G. Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis—review of the literature. Eur J Med Res, 2011; 16(4): 139–144.
Karthaus M, Lehrnbecher T, Lipp HP, Kluge S, Buchheidt D. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients an evidence-based approach. Ann Hematol, 2015; 94:547-556.
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother, 2013; 69(5): 1162–1176.
Zonios D, Yamazaki H, Murayama N, Natarajan V, Palmore T, Childs R, Skinner J, Bennett JE. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis, 2014; 209(12):1941-1948.
Villafuerte-Gutierrez P, Villalon L, Losa JE andHenriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: A critical review and update. Advances in Hematology, 2014; 1–9.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JA, Mullen CA, Raad II, Rolston KV, Young JAH, Wingard JR. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis, 2011; 52:e56–93.
Prevention & Treatment of Cancer Related Infection,National Comprehensive Cancer Network (NCCN) guideline. 2015: V.2.2015.
Khalafallah A, Maiwald M, Hannan T, Abell S, Staker J, Supperamohan A. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favorable outcome during induction chemotherapy for acute leukemia. Intern Med J, 2012; 42(2): 131–136.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E and Lee J. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 2002; 346:225–234.
Shehab N, DePestel DD, Mackler ER, Collins CD, Welch K, Erba HP. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Pharmacotherapy, 2007; 27(7): 970–979.
Przepiorka D, Buadi FK, McClune B. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Pharmacotherapy, 2008; 28(1): 58–63.
Koh H, Hino M, Ohta K, Iino M, Urase F, Yamaguchi M, Yamanouchi J, Usui N, Yoshida M, Tanimoto M, Ohyashiki K, Urabe A, Tamura K, Kanamaru A, Masaoka T. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan. J Infect Chemother, 2013; 19(6):1126–1134.
Oyake T, Kowata S, Murai K, Ito S, Akagi T, Kubo K, Sawada K, Ishida Y. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial. Eur J Haematol, 2016;96(6):602-9.
Riedel A, Choe L, Inciardi J, Yuen C, Martin T, Guglielmo BG. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis, 2007; 7:70.
Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 2010; 116(24):5111–5118.
Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G; IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haem, 2011; 155(3):318–327.
Yeh TC, Liu HC, Hou JY, Chen KH, Huang TH, Chang CY, Liang DC. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer, 2014; 120(8): 1255-1262.
Klastersky J andPaesmans M. Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. Supportive Care in Cancer, 2007; 15(2), 137–141.